dolutegravir + cabotegravir

**Dolutegravir + cabotegravir** is a two-drug combination of HIV-1 integrase strand transfer inhibitors (INSTIs). Both agents inhibit the HIV integrase enzyme, blocking the integration of viral DNA into the host genome—a critical replication step. *Dolutegravir* is approved for the treatment of HIV-1 infection and is used in multiple fixed-dose combinations. *Cabotegravir* is a structural analogue of dolutegravir and exists both as an oral agent and as a long-acting injectable formulation; it is in advanced development for both HIV treatment and pre-exposure prophylaxis (PrEP)[2][4][6]. Both drugs display high potency with long elimination half-lives, enabling potential for infrequent dosing. The combination exploits synergistic blockade of HIV replication at the integrase step to prevent or control infection.